Resmed (RMD) Notes Payables (2015 - 2026)

Resmed (RMD) has 12 years of Notes Payables data on file, last reported at $259.9 million in Q1 2026.

• For the quarter ending Q1 2026, Notes Payables rose 2523.95% year-over-year to $259.9 million; the trailing twelve-month figure through Mar 2026 stood at $259.9 million (up 2523.95% YoY), and the FY2025 full-year result was $9.9 million, changed 0.0% from the prior year.
• Notes Payables for Q1 2026 stood at $259.9 million, roughly flat from $259.9 million in the prior quarter.
• Across five years, Notes Payables topped out at $259.9 million in Q1 2026 and bottomed at $9.9 million in Q3 2024.
• The 5-year median for Notes Payables is $9.9 million (2023), against an average of $54.1 million.
• The widest annual swing landed in 2022, when Notes Payables slipped 17.5%; it then jumped 2526.3% in 2025.
• A 5-year view of Notes Payables shows it stood at $9.9 million in 2022, then decreased by 0.02% to $9.9 million in 2023, then grew by 0.08% to $9.9 million in 2024, then surged by 2523.72% to $259.9 million in 2025, then grew by 0.01% to $259.9 million in 2026.
• The last three Notes Payables figures came in at $259.9 million (Q1 2026), $259.9 million (Q4 2025), and $259.9 million (Q3 2025), per Business Quant data.

Peer Comparison